Richard Vile

14PUBLICATIONS
58CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 05, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

|Apr 09, 2026
Retinopathy caused by a primary immune regulatory disorder - the spectrum of AIRE-associated retinopathy: case series and literature review.

Mohammad Anas, Andrew C Browning, Siying Lin

|Mar 24, 2026
The TCR in CAR T cell therapy: use it or lose it?

Olivia Liseth, Richard Vile

|Sep 25, 2025
Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma.

Richard G Vile

|Jul 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright

|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright

Pageof 3

Frequent Collaborators

5 joint publications

Alan Melcher

4 joint publications

Kevin J Harrington

3 joint publications

Thanich Sangsuwannukul

3 joint publications

Shane Foo